Zobrazeno 1 - 10
of 141
pro vyhledávání: '"Marc, Vooijs"'
Autor:
Lorena Giuranno, Eloy M. Roig, Carolien Wansleeben, Annette van denBerg, Arjan J. Groot, Ludwig Dubois, Marc Vooijs
Publikováno v:
Stem Cells Translational Medicine, Vol 9, Iss 7, Pp 799-812 (2020)
Abstract Hyperactivity of the NOTCH pathway is associated with tumor growth and radiotherapy resistance in lung cancer, and NOTCH/γ‐secretase inhibitors (GSIs) are a potential therapeutic target. The therapeutic outcome, however, is often restrict
Externí odkaz:
https://doaj.org/article/5940253b822140699faa623d3186f1dc
Autor:
Tom G. Keulers, Sten F. Libregts, Joel E.J. Beaumont, Kim G. Savelkouls, Johan Bussink, Hans Duimel, Ludwig Dubois, Marijke I. Zonneveld, Carmen López‐Iglesias, Karel Bezstarosti, Jeroen A. Demmers, Marc Vooijs, Marca Wauben, Kasper M.A. Rouschop
Publikováno v:
Journal of Extracellular Vesicles, Vol 10, Iss 14, Pp n/a-n/a (2021)
Abstract Tumour hypoxia is a hallmark of solid tumours and contributes to tumour progression, metastasis development and therapy resistance. In response to hypoxia, tumour cells secrete pro‐angiogenic factors to induce blood vessel formation and re
Externí odkaz:
https://doaj.org/article/af6b9ede953b475aa1ad89c65bcf4ab4
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Patient-derived cancer organoids have taken a prominent role in pre-clinical and translational research and have been generated for most common solid tumors. Cancer organoids have been shown to retain key genetic and phenotypic characteristics of the
Externí odkaz:
https://doaj.org/article/805ded051e514f6dac6533af7306a530
Autor:
Judith Hounjet, Marc Vooijs
Publikováno v:
Biomolecules, Vol 11, Iss 9, p 1369 (2021)
Aberrant Notch signaling has been found in a broad range of human malignancies. Consequently, small molecule inhibitors and antibodies targeting Notch signaling in human cancers have been developed and tested; however, these have failed due to limite
Externí odkaz:
https://doaj.org/article/dc3a17199d394f4296682a22f2cd1668
Autor:
Vincent Favaudon, Arturo Londoño-Vallejo, Marie Dutreix, Pierre Verrelle, Marc Vooijs, Sylvain Baulande, Mylène Bohec, Hamza Umut Karakurt, Sophie Leboucher, Arnaud Beddok, Sarah Bonnet-Boissinot, Sophie Heinrich, Eddy Quelennec, Lorena Giuranno, Sandra Curras-Alonso, Charles Fouillade
Purpose:One of the main limitations to anticancer radiotherapy lies in irreversible damage to healthy tissues located within the radiation field. “FLASH” irradiation at very high dose-rate is a new treatment modality that has been reported to spe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38ed6d7cae488680025a6bef70ead337
https://doi.org/10.1158/1078-0432.c.6528476
https://doi.org/10.1158/1078-0432.c.6528476
Autor:
Vincent Favaudon, Arturo Londoño-Vallejo, Marie Dutreix, Pierre Verrelle, Marc Vooijs, Sylvain Baulande, Mylène Bohec, Hamza Umut Karakurt, Sophie Leboucher, Arnaud Beddok, Sarah Bonnet-Boissinot, Sophie Heinrich, Eddy Quelennec, Lorena Giuranno, Sandra Curras-Alonso, Charles Fouillade
Supplementary data: text with embedded figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28ab07ef6cbc13589d483b0dd0ea6726
https://doi.org/10.1158/1078-0432.22473320
https://doi.org/10.1158/1078-0432.22473320
Publikováno v:
Cells, Vol 10, Iss 4, p 930 (2021)
Radiation therapy (RT) can induce an immunogenic variant of regulated cell death that can initiate clinically relevant tumor-targeting immune responses. Immunogenic cell death (ICD) is accompanied by the exposure and release of damage-associated mole
Externí odkaz:
https://doaj.org/article/b856b05209dd4da080b2da56b6259b5d
Autor:
Venus Sosa Iglesias, Jan Theys, Arjan J. Groot, Lydie M. O. Barbeau, Alyssa Lemmens, Ala Yaromina, Mario Losen, Ruud Houben, Ludwig Dubois, Marc Vooijs
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Background: Lung cancer is the leading cause of cancer death worldwide. More effective treatments are needed to increase durable responses and prolong patient survival. Standard of care treatment for patients with non-operable stage III-IV NSCLC is c
Externí odkaz:
https://doaj.org/article/0220edbc70dd4d41a14051264307e964
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Drug resistance is a major cause for therapeutic failure in non-small cell lung cancer (NSCLC) leading to tumor recurrence and disease progression. Cell intrinsic mechanisms of resistance include changes in the expression of drug transporters, activa
Externí odkaz:
https://doaj.org/article/fb23a057667d404db088623e534be117
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Hypoxia-inducible factor-2α (HIF-2α) plays an important role in tumor progression and metastasis. A number of studies have evaluated the correlation between HIF-2α overexpression and clinical outcome in cancer patients but yielded inconsistent res
Externí odkaz:
https://doaj.org/article/c85e4c4e698c4b8f81e6cb06c8e63384